Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
BIOA Quote, Financials, Valuation and Earnings
Last price:
$17.48
Seasonality move
:
21.49%
Day range:
$16.99 - $18.22
52-week range:
$2.88 - $24.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
69.87x
P/B ratio:
2.85x
Volume:
301.4K
Avg. volume:
565.4K
1-year change:
401.43%
Market cap:
$765.7M
Revenue:
$9M
EPS (TTM):
-$2.24
Analysts' Opinion
-
Consensus RatingBioAge Labs, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $53.33, BioAge Labs, Inc. has an estimated upside of 204.76% from its current price of $17.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing -31.43% downside risk from its current price of $17.50.
Fair Value
-
According to the consensus of 5 analysts, BioAge Labs, Inc. has 204.76% upside to fair value with a price target of $53.33 per share.
BIOA vs. S&P 500
-
Over the past 5 trading days, BioAge Labs, Inc. has overperformed the S&P 500 by 4.19% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioAge Labs, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioAge Labs, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioAge Labs, Inc. reported revenues of $3.1M.
Earnings Growth
-
BioAge Labs, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioAge Labs, Inc. reported earnings per share of -$0.72.
Enterprise value:
501.1M
EV / Invested capital:
--
Price / LTM sales:
69.87x
EV / EBIT:
--
EV / Revenue:
55.71x
PEG ratio (5yr expected):
-0.84x
EV / Free cash flow:
-6.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.8M
Return On Assets:
-24.8%
Net Income Margin (TTM):
-896.11%
Return On Equity:
-27.22%
Return On Invested Capital:
-26.5%
Operating Margin:
-923.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $9M | -- | $3.1M | |
| Gross Profit | -$162K | -$167K | $8.8M | -$47K | $3M | |
| Operating Income | -$48.4M | -$78.2M | -$92.8M | -$25.4M | -$28.4M | |
| EBITDA | -$48.2M | -$78M | -$92.6M | -$25.3M | -$28.4M | |
| Diluted EPS | -$1.87 | -$2.05 | -$2.24 | -$0.59 | -$0.72 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $25.3M | $357.1M | $286.8M | |
| Total Assets | -- | -- | $25.9M | $358.3M | $295.5M | |
| Current Liabilities | -- | -- | $58.2M | $27.8M | $20.1M | |
| Total Liabilities | -- | -- | $66.6M | $35.2M | $23.5M | |
| Total Equity | -- | -- | -$40.7M | $323.1M | $272.1M | |
| Total Debt | -- | -- | $14.2M | $8.5M | $5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.4M | -$51.5M | -$81.6M | -$5.1M | -$28.3M | |
| Cash From Investing | -$266K | -$366K | -$95.2M | -$26K | -$14.4M | |
| Cash From Financing | $34.9M | $381.2M | $11.5M | $24.9M | $16M | |
| Free Cash Flow | -$37.5M | -$51.9M | -$82.3M | -$5.2M | -$28.4M | |
BIOA
Sector
Market Cap
$765.7M
$23.9M
Price % of 52-Week High
72.92%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-3.34%
-1.88%
1-Year Price Total Return
401.43%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$16.68
200-day SMA
Buy
Level
$10.58
Bollinger Bands (100)
Buy
Level
11.31 - 20.77
Chaikin Money Flow
Sell
Level
-10M
20-day SMA
Sell
Level
$18.71
Relative Strength Index (RSI14)
Sell
Level
44.66
ADX Line
Sell
Level
21.91
Williams %R
Neutral
Level
-68.9127
50-day SMA
Sell
Level
$19.63
MACD (12, 26)
Sell
Level
-0.85
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
11.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.1383)
Buy
CA Score
(Annual)
Level (0.1493)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.1175)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Stock Forecast FAQ
In the current month, BIOA has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIOA average analyst price target in the past 3 months is $53.33.
-
Where Will BioAge Labs, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioAge Labs, Inc. share price will rise to $53.33 per share over the next 12 months.
-
What Do Analysts Say About BioAge Labs, Inc.?
Analysts are divided on their view about BioAge Labs, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioAge Labs, Inc. is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is BioAge Labs, Inc.'s Price Target?
The price target for BioAge Labs, Inc. over the next 1-year time period is forecast to be $53.33 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BIOA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioAge Labs, Inc. is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BIOA?
You can purchase shares of BioAge Labs, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioAge Labs, Inc. shares.
-
What Is The BioAge Labs, Inc. Share Price Today?
BioAge Labs, Inc. was last trading at $17.48 per share. This represents the most recent stock quote for BioAge Labs, Inc.. Yesterday, BioAge Labs, Inc. closed at $17.50 per share.
-
How To Buy BioAge Labs, Inc. Stock Online?
In order to purchase BioAge Labs, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BIOA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIOA
Sector
P/E ratio
--
21.37x
PEG ratio
-0.84x
-0.01x
P/B ratio
2.85x
1.72x
Price / LTM sales
69.87x
1.45x
Growth Metrics
BIOA
Sector
Revenue growth
--
3.44%
Earnings growth
-21.9%
15.03%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.63
-$0.22
Profitability
BIOA
Sector
Profitability FY 2025
$8.8M
$2.4M
Return on invested capital
-26.5%
-33.32%
Return on assets
-24.8%
-29.45%
Return on equity
-27.22%
-40.29%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
May
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
BIOA
Sector
Total cash
$281.1M
$25.7M
Short term investments
--
$22.7M
Total assets
$295.5M
$70.6M
Long term debt
$5M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
